学术发表 - 合源生物科技（天津）有限公司

Research and Development 科研管线

纳基奥仑赛认证医疗机构名单创新支付研发管线学术发表

发表时间：2024/12/07 来源：Blood - 2024 ASH Annual Meeting Abstract

Development of a Novel Allogeneic Super-γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors
发表时间：2024/12/05 来源：Blood - 2024 ASH Annual Meeting Abstract

Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia in China
发表时间：2024/12/03 来源：Blood Advances

Inaticabtagene Autoleucel (CNCT19) in Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
发表时间：2024/11/05 来源：Blood - 2024 ASH Annual Meeting Abstract

CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
发表时间：2024/11/05 来源：Blood - 2024 ASH Annual Meeting Abstract

Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-IN-ONE Site-Specific Integration Technology for Autoimmune Diseases
发表时间：2024/11/05 来源：Blood - 2024 ASH Annual Meeting Abstract

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

1 2 3 4

我们的目标专注细胞治疗领航健康未来